<DOC>
	<DOCNO>NCT00141297</DOCNO>
	<brief_summary>PD-0332991 may work cancer stop cancer cell multiply . PD-0332991 new class drug call cyclin-dependent kinase ( CDK inhibitor ) . This research study first time PD-0332991 give people . PD-0332991 take mouth daily .</brief_summary>
	<brief_title>A Study Of Oral Palbociclib ( PD-0332991 ) , A Cyclin-Dependent Kinase Inhibitor , In Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Cyclin-Dependent Kinase Inhibitor Proteins</mesh_term>
	<criteria>Advanced solid tumor ( exclude SCLC retinoblastoma ) follicular diffuse large cell nonHodgkin 's lymphoma , histologically cytologically proven diagnosis refractory intolerant establish therapy know provide clinical benefit condition ; tumor must express Rb Adequate blood cell count , kidney function liver function ECOG score 0 , 1 , 2 . Patients may tumor biopsy treatment . Prior stem cell bone marrow transplant Uncontrolled infection , unstable sever intercurrent medical condition , current drug alcohol abuse Active unstable cardiac disease history heart attack within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced cancer</keyword>
</DOC>